[go: up one dir, main page]

MX2020009762A - Composicion farmaceutica que incluye alquil sulfato de sodio. - Google Patents

Composicion farmaceutica que incluye alquil sulfato de sodio.

Info

Publication number
MX2020009762A
MX2020009762A MX2020009762A MX2020009762A MX2020009762A MX 2020009762 A MX2020009762 A MX 2020009762A MX 2020009762 A MX2020009762 A MX 2020009762A MX 2020009762 A MX2020009762 A MX 2020009762A MX 2020009762 A MX2020009762 A MX 2020009762A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
alkyl sulfate
sodium alkyl
composition including
including sodium
Prior art date
Application number
MX2020009762A
Other languages
English (en)
Inventor
Kenji Kusumoto
Sadahiro MIYAMURA
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2020009762A publication Critical patent/MX2020009762A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El objetivo de la presente invención es mejorar la disolución y la absorción de (S)-1-(3-(4-amino-3-((3,5-dimetoxifenil)etinil-1H- pirazolo[3,4-d]pirimidin-1-il-1-pirrolidinil)-2-propen-1-ona efectivo como un agente antitumoral de una formulación farmacéutica que comprende el mismo; se proporciona una composición farmacéutica que comprende (S)-1-(3-(4-amino-3-((3,5-d imetoxifenil)etinil-1H-pirazolo[3,4-d]pirimidin-1-il-1-pirrolidin il)-2-propen-1-ona en combinación con alquil sulfato de sodio que tiene un grupo alquilo que contiene de 10 a 18 átomos de carbono, en particular, con lauril sulfato de sodio.
MX2020009762A 2018-03-19 2019-03-18 Composicion farmaceutica que incluye alquil sulfato de sodio. MX2020009762A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018051620 2018-03-19
PCT/JP2019/011251 WO2019181876A1 (ja) 2018-03-19 2019-03-18 アルキル硫酸ナトリウムを含む医薬組成物

Publications (1)

Publication Number Publication Date
MX2020009762A true MX2020009762A (es) 2021-01-08

Family

ID=67987327

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009762A MX2020009762A (es) 2018-03-19 2019-03-18 Composicion farmaceutica que incluye alquil sulfato de sodio.

Country Status (22)

Country Link
US (1) US11833151B2 (es)
EP (3) EP4353222A1 (es)
JP (2) JP6918204B2 (es)
KR (1) KR102473372B1 (es)
CN (1) CN111867594A (es)
AU (1) AU2019239404B2 (es)
BR (1) BR112020018697A2 (es)
CA (1) CA3094431C (es)
DK (1) DK3769765T3 (es)
ES (1) ES2980333T3 (es)
FI (1) FI3769765T3 (es)
HU (1) HUE067430T2 (es)
MA (1) MA52093A (es)
MX (1) MX2020009762A (es)
MY (1) MY203305A (es)
PH (1) PH12020551412A1 (es)
PL (1) PL3769765T3 (es)
PT (1) PT3769765T (es)
RU (1) RU2759746C1 (es)
SG (1) SG11202008435SA (es)
TW (1) TWI790364B (es)
WO (1) WO2019181876A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250007056A (ko) 2016-03-04 2025-01-13 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
AU2019239404B2 (en) * 2018-03-19 2021-12-23 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
US20220023300A1 (en) * 2018-11-26 2022-01-27 Taiho Pharmaceutical Co., Ltd. Therapeutic and prophylactic method for tumor treatable with endocrine therapy by combined use of fibroblast growth factor receptor inhibitor with endocrine therapy
JPWO2023238929A1 (es) * 2022-06-10 2023-12-14

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3433239A1 (de) * 1984-09-11 1986-03-20 Bayer Ag, 5090 Leverkusen Feste arzneizubereitung enthaltend nitrendipin und verfahren zu ihrer herstellung
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
AU6853498A (en) * 1997-04-22 1998-11-13 Nippon Kayaku Kabushiki Kaisha Flutamide preparations and method for manufacturing the same
JP4117811B2 (ja) 1997-04-22 2008-07-16 日本化薬株式会社 フルタミド製剤及びその製法
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
IL153817A0 (en) 2000-07-19 2003-07-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
PL401637A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
DK1682138T3 (da) 2003-11-19 2011-04-18 Array Biopharma Inc Heterocykliske inhibitorer af MEK
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE602005004286T2 (de) 2004-06-11 2009-01-02 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs
MX2007004781A (es) 2004-10-20 2007-05-11 Applied Research Systems Derivados de 3-arilamino piridina.
AU2006257273A1 (en) * 2005-06-17 2006-12-21 Pfizer Inc. Alpha-(ARyl-Or heteroaryl-methyl)-beta-piperidinopropanoic acid compounds as orl1-receptor antagonists
AU2006272837B2 (en) 2005-07-21 2012-08-23 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of MEK
AU2006299338A1 (en) 2005-10-06 2007-04-12 Merck Sharp & Dohme Corp. Pyrazolopyrimidines as protein kinase inhibitors
DK1934174T3 (da) 2005-10-07 2011-08-01 Exelixis Inc Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
ATE507224T1 (de) 2005-11-15 2011-05-15 Array Biopharma Inc Verfahren und zwischenverbindungen zur herstellung von n4-phenyl-quinazolin-4-amin derivaten
WO2007087395A2 (en) 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
MX2008013675A (es) * 2006-04-26 2009-03-06 Supernus Pharmaceuticals Inc Preparaciones de liberacion controlada de oxcarbacepina que tienen perfil de liberacion sigmoidal.
EP1939197A1 (en) 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
KR101445892B1 (ko) 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암 치료용 조성물
EP2560007A1 (en) 2007-03-28 2013-02-20 Pharmacyclics, Inc. Identification of bruton's tyrosine kinase inhibitors
CN102727498B (zh) 2007-04-10 2016-08-03 埃克塞里艾克西斯公司 使用吡啶并嘧啶酮PI3Kα抑制剂的治疗方法
BRPI0818004B8 (pt) * 2007-10-16 2021-05-25 Biocon Ltd composição farmacêutica sólida administrável por via oral e o processo da mesma.
PE20110062A1 (es) 2008-06-19 2011-03-09 Astrazeneca Ab N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB0819105D0 (en) 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
AU2010243353B2 (en) 2009-04-30 2014-09-11 Astex Therapeutics Limited Imidazole derivatives and their use as modulators of Cyclin dependent Kinases
KR101483215B1 (ko) 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
EP2547698B1 (en) 2010-03-14 2015-07-29 The Translational Genomics Research Institute Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
CN106963741A (zh) * 2010-03-29 2017-07-21 Ea制药株式会社 含有苯基丙氨酸衍生物的医药制剂
DE102011015188A1 (de) 2010-03-29 2011-09-29 Herbert Kannegiesser Gmbh Verfahren zur Nassbehandlung, insbesondere zum Reinigen, von Gegenständen
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
PL2698372T3 (pl) 2011-04-06 2016-07-29 Taiho Pharmaceutical Co Ltd Nowy związek imidazooksazynowy lub jego sól
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
ES2516392T3 (es) 2012-01-19 2014-10-30 Taiho Pharmaceutical Co., Ltd. Compuesto de alquinilbenceno 3,5-disustituido y sal del mismo
US20140378422A1 (en) 2012-01-31 2014-12-25 Novartis Ag Combination of a RTK inhibitor with an anti-estrogen and use thereof for the treatment of cancer
ES2581065T3 (es) 2012-02-23 2016-08-31 Bayer Intellectual Property Gmbh Benzotienil-pirrolotriazinas sustituidas y usos de las mismas
PL2868660T3 (pl) 2012-07-02 2018-05-30 Taiho Pharmaceutical Co., Ltd. Środek wzmacniający działanie przeciwnowotworowe zawierający związek imidazooksazynowy
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
CN104903448B (zh) 2012-11-26 2017-07-11 罗氏创新中心哥本哈根有限公司 用于调节fgfr3的表达的组合物和方法
CA2902263A1 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
PT2986610T (pt) 2013-04-19 2018-03-09 Incyte Holdings Corp Heterociclos bicíclicos como inibidores de fgfr
PL3543355T3 (pl) 2013-06-20 2021-05-31 Taiho Pharmaceutical Co., Ltd. Sposób przewidywania skuteczności terapeutycznej inhibitora PI3K/AKT/mTOR na podstawie ekspresji PHLDA1 lub PIK3C2B
ES2819398T3 (es) * 2013-07-18 2021-04-15 Taiho Pharmaceutical Co Ltd Agente terapéutico para el cáncer resistente al inhibidor de FGFR
WO2015008839A1 (ja) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤の間歇投与用抗腫瘍剤
EP3125936B1 (en) * 2014-03-31 2019-05-08 Debiopharm International SA Fgfr fusions
RU2020119391A (ru) 2014-04-25 2020-07-03 Чугаи Сейяку Кабусики Кайся Получение тетрациклического соединения, содержащегося в высокой дозе
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
JP6227767B2 (ja) * 2014-05-12 2017-11-08 株式会社日立製作所 情報処理装置、その処理方法、及び入出力装置
EP3200775B1 (en) 2014-10-03 2019-11-20 Novartis AG Combination therapies
MA41350A (fr) 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv Synthèse d'un inhibiteur de la tyrosine kinase de bruton
CN105859721B (zh) 2015-01-22 2018-04-17 浙江京新药业股份有限公司 一种伊布鲁替尼的制备方法
CA2975673A1 (en) 2015-02-05 2016-08-11 Tyrnovo Ltd. Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer
US10792284B2 (en) 2015-02-12 2020-10-06 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment
JPWO2016136928A1 (ja) 2015-02-27 2017-08-31 大鵬薬品工業株式会社 イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法
CN111393446B (zh) 2015-03-31 2022-12-20 大鹏药品工业株式会社 3,5-二取代的苯炔基化合物晶体
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
AU2016286091B2 (en) 2015-06-29 2021-02-04 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
EP3120851A1 (en) 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
EP3690059A1 (en) * 2015-07-24 2020-08-05 Debiopharm International SA Fgfr expression and susceptibility to an fgfr inhibitor
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP6860919B2 (ja) 2015-11-19 2021-04-21 国立大学法人金沢大学 間葉系ｋｒａｓ変異型がん治療剤
KR20250007056A (ko) 2016-03-04 2025-01-13 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
JP2018002662A (ja) 2016-07-01 2018-01-11 大鵬薬品工業株式会社 キノリルピロロピリミジル縮合環化合物を合成するために有用な中間体
JP6296308B1 (ja) 2016-09-26 2018-03-20 ツジカワ株式会社 ロール装置
AU2018207464B2 (en) 2017-01-10 2020-05-14 Novartis Ag Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor
AU2019239404B2 (en) * 2018-03-19 2021-12-23 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
EP3882248A4 (en) 2018-11-09 2022-07-06 Taiho Pharmaceutical Co., Ltd. ANALOGS OF DIMETHOXYBENZENE COMPOUNDS, METHODS FOR THE ANALYSIS OF THE SAME COMPOUNDS AND STANDARD PRODUCTS OF THE SAME COMPOUNDS
WO2020095452A1 (ja) 2018-11-09 2020-05-14 大鵬薬品工業株式会社 ジメトキシベンゼン化合物の製造方法
US20220023300A1 (en) 2018-11-26 2022-01-27 Taiho Pharmaceutical Co., Ltd. Therapeutic and prophylactic method for tumor treatable with endocrine therapy by combined use of fibroblast growth factor receptor inhibitor with endocrine therapy
WO2020170355A1 (ja) 2019-02-20 2020-08-27 大鵬薬品工業株式会社 Ｆｇｆｒ１変異腫瘍の治療方法
EP3932425A4 (en) 2019-02-28 2022-12-07 Taiho Pharmaceutical Co., Ltd. CANCER THERAPY WITH 3,5-DISUBSTITUTED BENZENE ALKINYL COMPOUND AND IMMUNE CHECKPOINT INHIBITOR
WO2020256096A1 (ja) 2019-06-21 2020-12-24 大鵬薬品工業株式会社 悪性腫瘍の治療方法

Also Published As

Publication number Publication date
US11833151B2 (en) 2023-12-05
EP3769765A4 (en) 2021-12-15
MY203305A (en) 2024-06-23
JPWO2019181876A1 (ja) 2020-10-08
KR102473372B1 (ko) 2022-12-05
PH12020551412A1 (en) 2021-09-01
EP4353222A1 (en) 2024-04-17
JP7322103B2 (ja) 2023-08-07
RU2759746C1 (ru) 2021-11-17
EP3769765B1 (en) 2024-04-17
PL3769765T3 (pl) 2024-06-10
EP4470621A2 (en) 2024-12-04
KR20200131873A (ko) 2020-11-24
EP4470621A3 (en) 2025-05-07
AU2019239404B2 (en) 2021-12-23
AU2019239404A1 (en) 2020-11-05
EP3769765A1 (en) 2021-01-27
CA3094431C (en) 2023-06-27
CA3094431A1 (en) 2019-09-26
HUE067430T2 (hu) 2024-10-28
JP6918204B2 (ja) 2021-08-11
BR112020018697A2 (pt) 2020-12-29
WO2019181876A1 (ja) 2019-09-26
JP2021167346A (ja) 2021-10-21
CN111867594A (zh) 2020-10-30
TWI790364B (zh) 2023-01-21
TW201938564A (zh) 2019-10-01
US20210030755A1 (en) 2021-02-04
DK3769765T3 (da) 2024-05-13
SG11202008435SA (en) 2020-10-29
FI3769765T3 (fi) 2024-05-15
PT3769765T (pt) 2024-05-13
ES2980333T3 (es) 2024-09-30
MA52093A (fr) 2021-01-27

Similar Documents

Publication Publication Date Title
PH12020551412A1 (en) Pharmaceutical composition including sodium alkyl sulfate
CL2018003604A1 (es) Composiciones farmacéuticas para terapia combinada (divisional solicitud 201701983)
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
MX2022007968A (es) Dosificacion de gamma-hidroxibutirato (ghb).
CL2019003892A1 (es) Nuevos derivados de azaquinolina.
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
BR112018010024A2 (pt) compostos e composições úteis no tratamento de distúrbios relacionados a ntrk
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
BRPI0610108B8 (pt) compostos promotores de apoptose e composição que compreende os ditos compostos
BR112014017716A8 (pt) composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
BR112014005617A2 (pt) tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv
CL2008001756A1 (es) Agente de arn de interferencia (iarn); composicion farmaceutica que lo comprende; y su uso para tratar procesos patologicos mediados al menos en parte por la expresion del canal de sodio epitelial alfa (alfa-enac)
PH12019550249A1 (en) Solid compositions for oral administration
GT200900049A (es) Derivados de 2-aril-6-fenil-imidazo [1,2-a]piridinas, su preparacion y su aplicacion terapeutica
CL2008001721A1 (es) Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
GEP20227373B (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
BRPI0515316A (pt) compostos de imidazoquinolina
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
PH12022551468A1 (en) Compounds active towards nuclear receptors
BR112016004358A8 (pt) combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit
WO2020097568A3 (en) Oligosaccharide compositions and methods of use thereof
CL2015002721A1 (es) Formulaciones oftálmicas
MX2022007265A (es) Compuestos activos frente a receptores nucleares.